Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  AB Science    AB   FR0010557264

AB SCIENCE

(AB)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
04/02/2020 04/03/2020 04/06/2020 04/07/2020 04/08/2020 Date
7.75(c) 7.23(c) 7.49(c) 7.28(c) 7.17(c) Last
259 426 230 260 147 710 147 296 148 709 Volume
-1.77% -6.71% +3.60% -2.80% -1.51% Change
More quotes
Financials (EUR)
Sales 2019 1,55 M
EBIT 2019 -21,4 M
Net income 2019 -
Debt 2019 -
Yield 2019 -
Sales 2020 1,60 M
EBIT 2020 -22,5 M
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales2019 207x
Capi. / Sales2020 200x
Capitalization 320 M
More Financials
Company
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals. 
Sector
Pharmaceuticals
Calendar
04/30Earnings Release
More about the company
Latest news on AB SCIENCE
04/07SCIENCE : Letter to AB Science stakeholders on COVID-19 pandemic impact on AB Sc..
AQ
03/31AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Scl..
GL
03/12SCIENCE : AB Science will present results from its Phase 3 AB07015 study in seve..
GL
03/09SCIENCE : Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 re..
PU
03/09SCIENCE : AB Science is providing a summary of the live webcast held on 06 March..
GL
03/09AB Science is providing a summary of the live webcast held on 06 March 2020 w..
GL
03/05AB Science will host a live webcast on masitinib in Progressive Forms of Mult..
GL
03/02SCIENCE : AB Science announces a new fundraising of EUR 12.3 million
GL
03/02SCIENCE : AB Science will host a live webcast on masitinib in Progressive Forms ..
GL
03/02AB Science will host a live webcast on masitinib in Progressive Forms of Mul..
GL
02/26AB SCIENCE : Provisional calendar
CO
02/20AB Science announces positive top-line Phase 2B/3 results for oral masitinib ..
GL
01/08AB SCIENCE : announces that FDA green-lights U.S. patient enrollment in masitini..
AQ
2019SCIENCE : AB Science announces the publication of new results in the peer-review..
GL
2019AB Science announces the publication of new results in the peer-reviewed jour..
GL
More news
News in other languages on AB SCIENCE
04:30aEN DIRECT DES MARCHES : Peugeot, Worldline, ArcelorMittal, Europcar, Biosynex..
03:05aDonald Trump se paie l'OMS, Mauro Ferrari se paie l'UE
04/07SCIENCE : Lettre aux partenaires d'AB Science concernant l'impact de la pandémie..
04/01AB SCIENCE : plus forte hausse du SRD à la clôture du mercredi 1er avril 2020
03/31SCIENCE : AB Science annonce que la FDA autorise le recrutement de patients aux ..
More news
Chart AB SCIENCE
Duration : Period :
AB Science Technical Analysis Chart | AB | FR0010557264 | MarketScreener
Technical analysis trends AB SCIENCE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 9,50  €
Last Close Price 7,17  €
Spread / Highest target 39,5%
Spread / Average Target 32,5%
Spread / Lowest Target 25,5%
Managers
NameTitle
Alain Moussy Chairman, CEO & Scientific Director
Laurent Guy Chief Financial Officer
Christian Fassotte Global Chief Medical Officer
Antonello Cervone Director-Information Technology
Edita Dolimier Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
AB SCIENCE35.32%353
MERCK KGAA-8.08%45 855
KYOWA KIRIN CO., LTD.1.18%11 706
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-0.51%10 851
JAZZ PHARMACEUTICALS PLC-29.52%5 906
BETTA PHARMACEUTICALS CO., LTD.1.95%4 381